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Myotonic Dystrophy—A Progeroid
Disease?
Peter Meinke*, Stefan Hintze, Sarah Limmer and Benedikt Schoser
Friedrich-Baur-Institute at the Department of Neurology, University Hospital, Ludwig-Maximilians-University Munich, Munich,
Germany
Myotonic dystrophies (DM) are slowly progressing multisystemic disorders caused by
repeat expansions in the DMPK or CNBP genes. The multisystemic involvement in
DM patients often reflects the appearance of accelerated aging. This is partly due to
visible features such as cataracts, muscle weakness, and frontal baldness, but there are
also less obvious features like cardiac arrhythmia, diabetes or hypogammaglobulinemia.
These aging features suggest the hypothesis that DM could be a segmental progeroid
disease. To identify the molecular cause of this characteristic appearance of accelerated
aging we compare clinical features of DM to “typical” segmental progeroid disorders
caused by mutations in DNA repair or nuclear envelope proteins. Furthermore, we
characterize if this premature aging effect is also reflected on the cellular level in DM and
investigate overlaps with “classical” progeroid disorders. To investigate the molecular
similarities at the cellular level we use primary DM and control cell lines. This analysis
reveals many similarities to progeroid syndromes linked to the nuclear envelope. Our
comparison on both clinical and molecular levels argues for qualification of DM as a
segmental progeroid disorder.
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INTRODUCTION
Myotonic dystrophies (DM) are slowly progressing multisystemic disorders characterized
by myotonia, muscle weakness, cataracts, and cardiac arrhythmia that can evolve into
cardiomyopathy, insulin insensitivity and diabetes, testicular failure, and hypogammaglobulinemia
(1, 2). The spectrum of DMs includes two types: type 1 (DM1) and type 2 (DM2) which are caused
by mutations in two different genes. The age of onset of DMs ranges from congenital forms at
birth to late onset at ∼70 years. Clinical symptoms cover muscular weakness, cataracts, balding,
skin changes, and diabetes mellitus, often mirroring the appearance of accelerated aging. While the
pathomechanism of DM has been shown to be a general splicing defect, it remains unclear what
genes and splice variants yield particular pathologies in the affected tissues. Here, we provide a
clinical description of aging symptoms in DM and compare this to “typical” progeroid disorders
which mimic physiological aging and are caused by mutations in nuclear envelope (NE) proteins
or DNA-repair proteins. Furthermore, we directly investigate some molecular hallmarks of aging
in primary cell lines of DM patients.
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MYOTONIC DYSTROPHY
Myotonic dystrophy (DM) can be caused by mutations in two
genes: DMPK and CNBP. In both cases the disease is caused by
an expansion of repeat elements within non-coding regions of
the genes. Those repeats are transcribed and therefore contained
within the pre-spliced mRNA. It is thought that RNA containing
the expanded repeat forms hairpin structures and accumulates
in foci in the nucleus. Several RNA-binding proteins are then
recruited to these foci where they interact strongly with the
mutant RNA. Among these proteins are MBNL proteins which
are involved in alternative splicing (3). The accumulation of
these proteins in the mRNA foci is thought to result in their
depletion from the rest of the nucleus, resulting in turn in
general mis-splicing and toxicity. This mis-splicing tends to
revert the splicing pattern to comprise many embryonic splice
variants. Phenotypically myotonic dystrophy is an autosomal
dominant disease with predominant myotonia and muscle
wasting. Furthermore eyes, heart, bone, skin, the endocrine
system, gastrointestinal organs, and the central as well as the
peripheral nervous system can be affected. The repeat length can
vary between different tissues significantly (4). This complicates
a prediction of the clinical development of patients as the repeat
length is usually measured in DNA gained from blood.
DM1 causing mutations are an expansion of a CTG repeat
in the 3’ UTR of the DMPK gene (5). The general tendency is
that the longer the expanded repeat the more severe the resulting
phenotype is. Anticipation is commonly observed; the number
of repeats typically increases in offspring over their parents so
that the heritable disease tends to be of increasing generational
severity. Up to 35 CTG triplets are considered normal, a repeat
length between 35 and 49 is considered to be a premutation.
Between 50 and ∼150 repeats have been observed in a mild
expression of the phenotype and ∼100 to 1000 CTG repeats
were identified in patients with classical DM. Repeats consisting
of more than 1,000 CTG-triplets result in congenital DM, the
most severe expression of the disease. The sexual inheritance also
affects the severity of the disease: maternal inheritance results in
more severe clinical features than paternal inheritance (6, 7).
Milder DM phenotypes can encompass cataracts, mild
myotonia, or diabetes mellitus only, and the age of onset ranges
between 20 and 70 years (8). Additional symptoms described in
classical DM1 include distal muscle weakness, fatigue, cardiac
conduction defects, neuropathy, endocrinopathies (on top of
diabetes mellitus), and alopecia. Age of onset for the classical
phenotype ranges between 10 and 30 years. In congenital
DM1 affected children suffer severe and generalized weakness,
hypotonia and respiratory problems after birth. One study
further found that DM1 patients may have an increased risk of
skin cancer (9).
DM2 mutations are located within intron 1 of the CNBP
gene: more than 75 CCTG repeats have been described as disease
causing (10). Unlike DM1 there is no described correlation
between repeat length and disease severity in DM2. DM2 is
considered a clinically more benign disorder than DM1 (11)
and can be distinguished by a proximal muscular dystrophy and
sparing of facial muscles (11), and the lack of a congenital form or
the severe central nervous system involvement observed in DM1
(10, 12).
The fact that DM1 and DM2 are not clinically identical
indicates that there are additional factors contributing to the
disease pathomechanism besides the sequestration of splicing
factors. In DM2 the repeat expansions tend to be longer than
in DM1 so that one would expect DM2 to be more severe, but
the opposite is the case: DM2 is clinically more benign. Thus it is
possible that apart from the RNA toxicity the respective gene loci
are contributing in different ways to the phenotype.
Due to its multisystemic involvement DM was suggested
decades ago to be a segmental progeroid syndrome (13). Later
it was also proposed as a model for premature muscle aging
(14) and it is possible that in some mild cases DM might mimic
sarcopenia (15, 16). Skin abnormalities frequently observed in
DM1 and DM2 are also regarded as indicators for premature
aging (17).
NUCLEAR ENVELOPE LINKED
PROGEROID SYNDROMES
A group of progeroid disorders is caused by mutations in
proteins of the nuclear envelope (NE) and also proteins involved
in their processing. The NE is a double membrane system
enclosing the genome in eukaryotic cells (18). Nuclear envelope
transmembrane proteins (NETs) reside within the NE and it
is underlaid by a meshwork of intermediate filament proteins,
the nuclear lamina (19, 20). NE proteins lost or mutated in
progeroid syndromes include lamin A and BAF. Apart from
progeroid syndromes mutations in the lamin A encoding gene
LMNA cause several tissue specific diseases (including muscular
dystrophy, neuropathy and lipodystrophy). The progeroid
syndromes caused by LMNAmutations encompass Hutchinson-
Gilford progeria syndrome (HGPS), mandibuloacral dysplasia
(MAD), Malouf syndrome, and several atypical progeroid
syndromes that cannot be assigned clearly. Lamin A is
an intermediate filament protein which undergoes post-
translational processing for farnesylation. It has functions
in mechanical stability, higher-order genome organization,
chromatin regulation, transcription, DNA replication, and DNA
repair (21). The major protein involved in its post-translational
processing is the zinc metalloprotease STE24, encoded by the
ZMPSTE24 gene. Mutations in the ZMPSTE24 gene cause
mandibuloacral dysplasia (MAD) and restrictive dermopathy
(RD). BAF (barrier to autointegration factor), a DNA binding
protein, is encoded by the BANF1 gene. Its functions include
chromatin remodeling, gene expression, and DNA damage repair
(22). It has been shown to interact with the LEM domain
containing NETs emerin, MAN1 and Lap2β as well as with lamin
A (23–25).
Hutchinson-Gilford progeria syndrome (HGPS) is most
commonly caused by the de novo heterozygous LMNA mutation
c.1824C>T; p.G608G which activates a cryptic splice site and
causes the deletion of 50 amino acids. This deletion includes
the cleavage site necessary for maturation of lamin A by post-
translational processing (26, 27). Affected individuals appear
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healthy at birth, but develop a progeroid phenotype within 1–
2 years. This comprises a short stature, low body weight, early
loss of hair, loss of subcutaneous fat, localized scleroderma-like
skin conditions, osteolysis, and facial features resembling aging
(small face and jaw, prominent eyes, pinched nose, thin lips, and
protruding ears). In most cases cardiovascular problems are the
reason for death in the second decade of life (28, 29).
Mandibuloacral dysplasia (MAD) can be caused by recessive
mutations in LMNA [MADA, (30)] or ZMPSTE24 [MADB,
(31)]. While the LMNA mutations tend to be homozygous
or compound heterozygous missense mutations, ZMPSTE24
mutations resulting in MADB tend to be a combination of
missense and nonsense mutations (32). Patients are characterized
by postnatal growth retardation, craniofacial anomalies with
mandibular hypoplasia, skeletal malformations, osteolysis of
distal phalanges, and clavicles, skin changes such as atrophy,
and speckled hyperpigmentation, insulin resistance, and diabetes,
and lipodystrophy which appears to be partial in MADA and
generalized in MADB (32).
Restrictive dermopathy (RD) is caused by homozygous
or compound heterozygous nonsense ZMPSTE24 mutations
resulting in a loss of the protein (33). The term RD describes
a rare, lethal, genodermatosis. Affected children die before
birth or within the first week of life. Clinical features include
tightly adherent thin skin, prominent vessels, characteristic facial
features (“O” shaped mouth), generalized joint contractures,
dysplasia of clavicles and respiratory insufficiency (32, 34).
Malouf syndrome is caused by heterozygous LMNAmutations
within the N-terminal parts of lamin A. In 2003 mutations
were identified in patients originally described as suffering
from Werner syndrome, but with no mutation in the RECQL2
gene and therefore named atypical Werner syndrome (35)–
though if the clinical phenotypes were actually matching Werner
syndrome was not absolutely clear (36, 37). Later work (38)
noted the phenotypic similarity to patients described by Malouf
et al. (39). Described clinical findings include hypergonadotropic
hypogonadism, cardiomyopathy, blepharoptosis, mild mental
retardation, prominent nasal bones, scleroderma-like skin, and
lipodystrophy (35, 38, 39).
In addition to these progeroid disorders there are several
cases of so called atypical progeroid syndromes caused by LMNA
mutations. These cases are often linked to a specific mutation
and show overlaps between well described LMNA or ZMPSTE24
linked diseases. Therefore it’s not possible to assign them clearly
to a syndrome (40–44).
Nestor-Guillermo progeria syndrome (NGPS) is caused by
recessive mutations in the BANF1 gene (45). Patients start
to develop a failure to thrive at age of 2, the skin becomes
dry and atrophic and they develop a generalized lipoatrophy,
osteoporosis, and osteolysis.
Amongst these several NE-linked progeroid syndromes, the
age of onset and life expectancy vary, but similarities include
skin abnormalities (scleroderma-like, atrophy or speckled
hyperpigmentation), osteolysis/osteoporosis, loss of hair, cardiac
involvement, insulin resistance, typical facies, and in some cases
muscular weakness. No noteworthy increased risk of cancer
amongst these disorders has been reported (Table 1).
DNA Repair Linked Progeroid Syndromes
Another group of progeroid diseases are caused by mutations
in DNA-repair proteins. Those encompass mutations in
RecQ protein-like helicases (RECQL) and nuclear excision
repair (NER) proteins. RecQ helicases play major roles in
genome maintenance and stability (46). Mutations in genes
encoding members of this protein family are causative
for the premature aging disorders Werner syndrome and
Bloom syndrome. NER proteins repair single stranded DNA
damage—particular UV-induced DNA damage. Progeroid
syndromes caused by mutations in NER protein encoding genes
include Cockayne syndrome, Xeroderma pigmentosum, and
Trichothiodystrophy.
Werner syndrome is caused by recessive mutations in
the RECQL2 protein encoding WRN gene that result in
a loss of protein by creating new stop codons or cause
frameshifts resulting in a premature stop codon (47). RECQL2
is involved in DNA double-strand break repair where it
regulates the pathway choice between classical and alternative
non-homologous end joining (48) and relocalizes from the
nucleolus to other nuclear regions upon DNA damage (49).
It is suggested to be involved in telomere replication (50).
Werner syndrome patients have scleroderma-like skin changes,
cataracts, osteoporosis, arteriosclerosis, diabetes mellitus,
cancer, characteristic “birdlike” facies, and can have alopecia
(51).
Mutations in the BLM gene, encoding RECQL3, cause Bloom
syndrome. The inheritance is recessive, and mutations result in a
loss of protein or loss of function (52, 53). RECQL3 is involved
in DNA replication and repair, where it acts in several steps
during homologous recombination during DNA double-strand
break repair (54). Patients present with pre- and postnatal growth
deficiency, UV-sensitivity, hypo-, and hyperpigmented skin, and
predisposition to malignancy (55).
Cockayne syndrome (CS) is distinguished into type A [CSA,
caused by recessive ERCC8 mutations (56)] and type B [CSB,
caused by recessive ERCC6 mutations (57)]. CSA patients show
a progeroid appearance with slow growth and development,
skin photosensitivity, thin and dry hair, pigmentary retinopathy,
sensorineural hearing loss and dental caries (58). CSB patients
are characterized by failure to thrive, severe mental retardation,
congenital cataracts, loss of adipose tissue, joint contractures,
distinctive face with small, deep-set eyes, and prominent nasal
bridge, kyphosis, sensorineural hearing loss, and cachectic
dwarfism (59).
Xeroderma pigmentosum (XP) is a rare autosomal recessive
disorder with patients showing acute photosensitivity and a
predisposition to skin cancer on sun-exposed areas of the body
(60). XP is caused by mutations in the XPA, ERCC3, XPC,
ERCC2, DDB2, ERCC4, ERCC5, and POLH genes. Another
NER protein associated disease is Trichothiodystrophy (TTD).
Patients display a wide variety of clinical features which
includes cutaneous, neurologic and growth abnormalities as well
as intellectual/developmental disabilities, ocular abnormalities
and decreased fertility (61). Causative mutations have been
described in the ERCC3, GTF2H5, MPLKIP, GTF2E2, ERCC2,
and RNF113A genes.
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In general these DNA repair linked progeroid disorders
exhibit a frequent involvement of the skin (scleroderma-like,
hyperpigmentation, increased photosensitivity), osteoporosis,
and cataracts occur, and there is also frequently neuronal
involvement. In addition this group of disorders tends to have
an increased risk of cancer (Table 1).
DM—ACCELERATED AGING AT THE
MOLECULAR LEVEL?
Aging related defects can be observed at the cellular level in cells
from patients with premature-aging disorders. Cellular hallmarks
of aging include senescence, telomere attrition, genomic
instability, mitochondrial dysfunction, and loss of proteostasis
(62). There are observations of premature senescence in DM
cells — cells obtained from distal muscle of congenital DM1
patients show a reduced proliferative capacity and an increased
rate of telomere shortening. The reduced proliferative capacity
observed in these cells was thought to be caused by a p16
dependent premature senescence (63, 64). DM2 myoblasts have
also been shown to reach premature senescence, but in a
p16 independent manner (65). Congenital DM1, but not DM2
myoblasts show differentiation defects (66, 67). There are also
changes in epigenetic marks in both DM1 and DM2 patient
cells, suggesting possible changes to genome organization: DM2
myoblasts exhibit heterochromatin accumulation (68) and the
DM1 locus is methylated to varying degrees across the expanded
repeats (69) and especially in congenital samples (70).
Another aging-associated feature is mitochondrial
dysfunction. It is proposed that mitochondrial free radicals
cause oxidative damage which is a driving force in cellular
aging (71). Mutations in mitochondrial DNA (mtDNA) can
lead to premature aging (72, 73). Increased mtDNA deletions
have been reported in DM (74). Furthermore mis-regulation of
the mitochondrial protein CoQ10 has been described in DM
in generell (75) and EFTu, HSP60, GRP75 as well as Dienoyl-
CoA-Isomerase specifically in DM2 (76). Another aging-linked
feature is the loss of proteostasis. Proteostasis has been shown
to collapse during aging (77) and there are indications that this
occurs in DM1 and DM2: CTG repeat expressing mice activate
the ubiquitin-proteasome pathway (78) and altered protein
degradation has been shown in DM2 myotubes (76).
OVERLAPS WITH TYPICAL PROGEROID
DISORDERS
DNA repair failure is certainly involved in the expansion of
the repeats in both DM1 and DM2; this is potentially caused
by slippage of DNA polymerase (79, 80). NER has also been
shown to promote repeat expansion (81) and a polymorphism
theMSH3mismatch repair gene has been associated with somatic
repeat instability (82). However, there are also reports indicating
NE abnormalities in DM. In DM1 derived fibroblasts an altered
localization of lamin A, lamin B1, and the NET emerin have been
described (83). This altered localization includes distribution to
invaginations of the NE, also known as nucleoplasmic reticuli
(84). Knockdown of the zinc metalloprotease STE24, which is
mutated in the progeroid syndromes MADB and RD and is a
major player in the processing of prelamin A to mature lamin
A, results in an enrichment of nucleoplasmic reticuli (85).
MATERIALS AND METHODS
Patient and Controls
Primary human myoblast were obtained from the Muscle Tissue
Culture Collection (MTCC) at the Friedrich-Baur-Institute
(Department of Neurology, Ludwig-Maximilians-University,
Munich, Germany). All control and patient materials were
obtained with written informed consent of the donor. Ethical
approval for this study was obtained from the ethical review
committee at the Ludwig-Maximilians-University, Munich,
Germany (reference 45-14). Repeat length was diagnosed on
DNA extracted from blood. Age and sex of patients and controls
are listed in Table 2.
TABLE 2 | Primary myoblast cell lines used and characterization.
Sample Sex Age at biopsy in
years
Repeat length Muscle of origin Positive for Ki-67
staining in %
Positive for desmin
staining in %
Used for immune-
fluorescence
Used for
western blot
Ctrl-1 ♂ 43 – M. biceps brachii 22.3 96.2 yes yes
Ctrl-2 ♀ 36 – M. biceps brachii 42.0 68.4 yes no
Ctrl-3 ♀ 49 – M. vastus lateralis 27.0 95.2 yes yes
DM1-1 ♂ 38 200 unknown n.d. n.d. yes no
DM1-2 ♂ 34 240–430 M. deltoideus 16.6 70.1 yes yes
DM1-3 ♀ 33 300–500 unknown 26.6 83.3 yes yes
DM1-4 ♂ 27 400–600 unknown n.d. 100 yes no
DM1-5 ♀ 29 800–1500 unknown 37.9 50.3 yes yes
DM2-1 ♂ 31 n.d. unknown 57.6 48.0 yes yes
DM2-2 ♀ 32 n.d. M. vastus lateralis 43.0 86.0 yes yes
DM2-3 ♂ 41 n.d. M. rectus femoris 43.4 45.0 yes yes
DM2-4 ♀ 37 n.d. M. biceps brachii n.d. n.d. yes no
DM2-5 ♂ 35 n.d. M. biceps brachii 20.0 94.4 yes no
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Tissue Culture
Myoblasts were grown in tissue culture using skeletal muscle
cell growth medium (PeloBiotec, Munich, Germany). Cells
were kept from reaching confluency to avoid differentiation.
Passage numbers were matched for controls and patient cells for
the respective experiments, throughout all experiments passage
numbers 8 to 10 have been used. For differentiation DMEM
containing 5% HS, was used. Myotubes were differentiated
for 7 days. Cells were grown at 37◦C in a 5% CO2
incubator.
Immunohistochemistry
Myoblasts were fixed withmethanol (−20◦C). Following primary
antibodies were used for staining: Ki-67 (Thermo Scientific, RM-
9106-S0), emerin 5D10 and lamin A/C 4A7 (both provided
by Glenn E. Morris). All secondary antibodies were Alexafluor
FIGURE 1 | Cell cycle regulatory proteins in myotonic dystrophy. Western Blot and quantification of primary control, DM1 and DM2 myoblasts for cell cycle regulatory
proteins p21 (A) and p16 (B). DM1 samples are ordered according their diagnosed repeat length from left (small repeat) to right (long repeat).
FIGURE 2 | Lamina proteins in myotonic dystrophy. Western Blot and quantification of primary control, DM1 and DM2 myoblasts for lamin A and lamin C (A) and
lamin B1 (B). DM1 samples are ordered according their diagnosed repeat length from left (small repeat) to right (long repeat).
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FIGURE 3 | Nuclear envelope invaginations in myotonic dystrophy. Immunofluorescence staining of primary control, DM1 and DM2 myoblasts for (A) emerin and Ki-67
showing nuclear envelope invagination in DM1 and DM2 myoblasts, (B) confirmation of nuclear envelope invaginations by lamin A/C staining and (C) quantification of
these structures in DM and control cell lines—standard deviation is shown. White arrows indicate invaginations of the nuclear envelope. Scale bar 10µm.
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FIGURE 4 | Nuclear envelope invaginations in myotonic dystrophy and control myotubes. Immunofluorescence staining of primary control, DM1 and DM2 myotubes
for (A) emerin and (B) lamin A/C showing nuclear envelope invagination in DM1 myotubes. White arrows indicate invaginations of the nuclear envelope. Scale bar
10µm.
conjugated and generated in donkey with minimal species cross-
reactivity. DNA was visualized with DAPI (4,6-diamidino-2
phenylindole, dihydrochloride).
Microscopy and Image Analysis
All images were obtained using an Olympus FluoView
FV1000/BX 61microscope equipped with a 1.42 NA 60x objective
and 3x zoom magnification. Image analysis was performed using
ImageJ software. For quantification of nuclear invaginations at
least 100 nuclei were counted for each measurement with the
Olympus FluoView FV1000/BX 61 confocal microscope using
the Z-drive to investigate the whole nucleus. For each sample at
least two or three (depending on the fitness of each individual
cell line) biological replicates were analyzed.
Western Blotting
Whole protein extracts were generated from myoblast cell
cultures using an ultrasonic sonicator with a MS73 tip
(Bandelin Sonopuls). The proteins were separated by SDS
gel electrophoresis using 4–15% TGX gels (BioRad #456–
8087). Western blotting was performed using the Trans-Blot R©
TurboTM system (BioRad). Proteins were transferred to low
fluorescent PVDF membranes (part of Trans-Blot R© TurboTM
RTA Transfer Kit #170-4274). Membranes were blocked with
5% BSA or 5% skim milk in 1xTBS/0, 1% Tween R© 20.
Following primary antibodies were used: lamin A/C 4A7
(provided by Glenn E.Morris), lamin B1 (D4Q4Z, Cell Signaling)
p16INK4A (ab108349, Abcam), p21 (Cell Signaling #2947). For
quantificationmouse antiGAPDH (Milipore #MAB374) or rabbit
antiGAPDH (Cell Signaling GAPDH (D16H11) XP #5174) were
used. As secondary antibodies we used donkey anti-mouse IRDye
680RD, donkey anti-mouse IRDye 800CW, donkey anti-rabbit
IRDye 680RD and donkey anti-rabbit IRDye 800 CW.All western
blot images were obtained using a Licor FC. Quantification was
done using the Licor ImageStudio Software. Western blots were
repeated at least two times to confirm the results.
RESULTS
As cellular senescence is a hallmark of aging we decided to
initially analyze cell cycle proteins linked to senescence in our
primary human myoblast cell lines. First, we used Western blot
analysis to quantify the expression of p21 and p16 (Figure 1).
P21 is an inhibitor of the cell cycle (86), which fails to be up-
regulated in DM2myoblasts during differentiation (87). Western
blot analysis of our myoblast cell lines shows only small changes
in p21 expression (Figure 1A), however this may be within the
observed expression level variations in primary myoblasts. P16 is
a tumor suppressor protein that has previously been shown to
be mis-regulated in congenital DM1 samples (63). There were
no changes in p16 expression except in the DM1 cell line with
the longest repeat where the expression was elevated. The next
step was to quantify lamin B1, another senescence associated
biomarker (88) which has not been investigated in DM before.
While we do not see lamin B1 changes in DM2 myoblasts, it was
down-regulated in all DM1 myoblasts tested (Figure 2B).
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The results of the lamin B1 quantification led us to
further investigate effects on NE proteins. For this we
quantified the expression of the other lamin subtypes A
and C, finding that lamin A is strongly down-regulated in
DM1 (Figure 2A). Immunofluorescence staining for lamin
A/C shows an increased number of nuclei with invaginations
in DM1 and DM2 myoblasts (Figure 3B). This has been
confirmed and quantified by staining with the NET emerin
(Figures 3A,C). For DM1, primary patient cell lines with
longer CTG repeats show a greater percentage of nuclei
with nuclear invaginations (Figure 3C). Co-staining with the
proliferation marker Ki-67 revealed that all cells with nuclear
invaginations are negative for Ki-67 and hence senescent.
Staining of differentiated myotubes with lamin A/C and emerin
shows the presence of nuclear invaginations in DM1 myotubes
(Figures 4A,B).
DISCUSSION
The differences in cell cycle control described in DM1 and
DM2 myoblasts gave rise to the idea that there are different
pathomechanisms in each DM type. While for DM2 a down-
regulation of the cell cycle inhibitor p21 has been shown (87),
there is a reported mis-regulation of p16 in congenital DM1
(63). We can confirm both effects in our DM patient myoblasts,
although the effects observed by us are not very strong and the
mis-regulation of p16 in DM1 seems to be restricted to longer
repeats (Figure 1).
Looking for a better senescence marker we quantified
lamin B1, a protein of the NE that has been shown to be
down-regulated in HGPS (89), cellular senescence (90) and
normal aging (91). The down-regulation of lamin B1 occurs
specifically in DM1 myoblasts and is independent of the repeat
length (Figure 2B). This indicates that it could be a more
relevant marker for DM1 in general than p16. Furthermore,
the strong down-regulation of lamin A (Figure 2A) confirms
that there are strong effects on the expression of nuclear
lamina proteins in DM1. The composition of the nuclear
lamina is important to achieve its multiple functions including
mechanical stability, chromatin organization, transcriptional
regulation, and response to oxidative stress (92, 93)–and
the down-regulation of the lamins A and B1 is potentially
having an effect on all these functions thus contributing to
the phenotype.
Further evidence of NE involvement in DM comes from the
enrichment of nuclear envelope invaginations in DM myoblasts
(Figures 3, 4). DM myoblasts show more nuclei with these
structures, with the strongest effects being observed in DM1.
Moreover, all nuclei with invaginations have exited the cell cycle.
In contrast to the lamin B1 levels, there appears to be a correlation
of repeat length in DM1 and the percentage of nuclei positive
for NE invaginations. The longer the diagnosed DM1 repeat
the more myoblast nuclei in primary cell lines gained from
those patients have invaginations of the nuclear envelope. This
could be another overlap to NE-linked progeroid syndromes:
knockdown of ZMPSTE24 also results in an enrichment of
NE invaginations (85) and the loss of ZMPSTE24 in human
FIGURE 5 | Myotonic dystrophy as a facet of progeroid syndromes? Schematic of affected nuclear regions and pathways in DM and nuclear envelope as well as DNA
repair linked progeroid syndromes.
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results in RD, the most severe NE-linked progeroid syndrome
(32). A possible explanation of how this contributes to the
disease pathology is that mis-regulation of lamina proteins
results in NE aberrations which force the cell to exit the
cell cycle and enter senescence. Consequently, this might
deplete the pool of myoblasts during muscle regeneration
and contribute to the muscular dystrophy in DM via failed
regeneration.
Taken together our results suggest that there is on
both the clinical and molecular level clear evidence
that DM reflects facets of segmental progeroid disorders
(Figure 5).
CONCLUSION
DMs qualify by clinical phenotypes as well as molecular features
as segmental progeroid syndromes. In DM1 the composition
of the NE is altered and there is an enrichment of nuclear
invaginations likely contributing to the phenotype. As several
NE-linked syndromes have muscle involvement, this further
suggests the possibility of an overlap between NE-linked
progseroid syndromes and DM1.
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